Weekly Investment Analysts’ Ratings Updates for Horizon Pharma PLC (HZNP)

Several brokerages have updated their recommendations and price targets on shares of Horizon Pharma PLC (NASDAQ: HZNP) in the last few weeks:

  • 8/10/2017 – Horizon Pharma PLC had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $18.00 price target on the stock, up previously from $17.00.
  • 8/9/2017 – Horizon Pharma PLC had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $17.00 price target on the stock, up previously from $13.00.
  • 8/9/2017 – Horizon Pharma PLC had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $9.00 price target on the stock, down previously from $10.00.
  • 8/8/2017 – Horizon Pharma PLC was given a new $16.00 price target on by analysts at UBS AG. They now have a “buy” rating on the stock.
  • 8/7/2017 – Horizon Pharma PLC was given a new $18.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 7/31/2017 – Horizon Pharma PLC was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/31/2017 – Horizon Pharma PLC was given a new $13.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “On Friday, July 28, HZNP shares came under pressure after concerns emerged that the company could lose its patent challenge for Ravicti’s ‘559 patent when it is ruled on by 9/30. Ravicti, for the treatment of urea cycle disorder, was 14% of HZNP’s sales in 2016. The stock closed down 3.95%, while the S&P 500 was down 0.13%.””
  • 7/28/2017 – Horizon Pharma PLC had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $17.00 price target on the stock.
  • 7/25/2017 – Horizon Pharma PLC was given a new $17.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 7/14/2017 – Horizon Pharma PLC had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $14.00 price target on the stock.
  • 7/11/2017 – Horizon Pharma PLC was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Horizon’s results from the primary care business units was much below expectations in the first quarter due to the implementation of a new commercial model where the company is contracting with pharmacy benefit managers and payers to help patients obtain access to its medicines. The company plans to overcome this underperformance by reducing certain costs in the primary care business unit in order to align its cost structure with the lower- than-expected sales. Due to the divestiture of Procysbi, the company now expects sales in 2017 to come around $985 million to $1.020 billion. On a positive note, Horizon is significantly increasing investments in one its key drugs, Krystexxa. Shares of the company have underperformed the Zacks classified industry.”
  • 6/24/2017 – Horizon Pharma PLC was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/16/2017 – Horizon Pharma PLC is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $13.00 price target on the stock.

Horizon Pharma PLC (HZNP) opened at 11.94 on Thursday. The stock’s 50 day moving average is $12.44 and its 200-day moving average is $13.70. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $23.44. The firm’s market cap is $1.94 billion.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.29. The business had revenue of $289.51 million for the quarter, compared to analyst estimates of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The company’s revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.56 EPS. On average, equities research analysts expect that Horizon Pharma PLC will post $1.03 earnings per share for the current fiscal year.

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.